Deals

BioNTech Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly and said the company could file for U.S. approval in mid-November if the data are positive. 'We will certainly be smarter in a fortnight,' Sahin said in a video interview with regional publisher VRM posted online late on Thursday, adding he expects first efficacy data in late October, early November. 'We are optimistic,' he said, adding if the data are positive, a request for emergency approval could be submitted to the US Food and Drug Administration (FDA) in mid-November.
More Description
Image URL

 

 

vlrPhone
vlrFilter
vlrMemos
Project of very low consumption, radiation and bitrate softphones
Multifunction Audio Filter with Remote Control
App to measure the quality of the voice
More Information
Free the Animation VR
AR
Play to reveal 3D images and 3D models
More Information

WhmSoft Moblog
Copyright (C) 2006-2021 WhmSoft
All Rights Reserved